Re-runs extraction for each period with period-end year from max(2023, current year − 2) through the current year, oldest first (up to three reporting years). This can take a long time.
Biotechnology medicines for oncology, inflammation, cardiovascular disease, and bone health.
Sector: Health care
US_AMGN
No intraday sparkline from the default exchange feed; Yahoo or day change may still appear below when available.
No price chart.
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: sec_companyfacts/318154
| Period | Issues |
|---|---|
| 2023-03-31 Q1 | ⚠Warn 2 |
| 2023-06-30 Q2 | ⚠Warn 1 |
| 2023-09-30 Q3 | ⚠Warn 1 |
| 2023-12-31 FY | ⚠Warn 2 |
| 2024-03-31 Q1 | ✗Errors 2Warn 3 |
| 2024-06-30 Q2 | ⚠Warn 1 |
| 2024-09-30 Q3 | ⚠Warn 1 |
| 2024-12-31 FY | ⚠Warn 1 |
| 2025-03-31 Q1 | ✗Errors 1Warn 1 |
| 2025-06-30 Q2 | ⚠Warn 1 |
| 2025-09-30 Q3 | ⚠Warn 1 |
| 2025-12-31 FY | ⚠Warn 1 |
| 2026-03-31 Q1 | ⚠Warn 1 |
Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueB USD | Operating profitB USD | D&AB USD | EBITDAB USD | Net profitB USD | Operating CFB USD | Capex + M&AB USD | AssetsB USD | EquityB USD | ROE (annualized) | Net debtB USD | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Q1 2026 (3M) | OK | 8.6 y/y 5.8% | 2.7 y/y 126.3% | 1.1 y/y -19.5% | 3.8 y/y 47.4% | 1.8 y/y 5.1% | 2.2 | -0.7 | 92.5 y/y 3.5% | 9.2 y/y 48.1% | 81.5% | 45.3 | Link |
| 2025-12-31 | FY 2025 (12M) | OK | 9.9 y/y 8.6% | 2.7 y/y 17.7% | 1.1 y/y -19.0% | 3.9 y/y 3.9% | 1.3 y/y 112.6% | 1.6 | -0.7 | 90.6 y/y -1.4% | 8.7 y/y 47.3% | 84.4% | 45.6 | Link |
| 2025-09-30 | Q3 2025 (3M) | OK | 9.6 y/y 12.4% | 2.5 y/y 23.4% | 1.3 y/y -6.4% | 3.8 y/y 11.3% | 3.2 y/y 13.6% | 4.7 | -0.4 | 90.1 y/y -0.8% | 9.6 y/y 27.8% | 50.3% | 45.1 | Link |
| 2025-06-30 | Q2 2025 (3M) | OK | 9.2 y/y 9.4% | 2.7 y/y 39.1% | 1.3 y/y -4.2% | 4.0 y/y 20.8% | 1.4 y/y 92.0% | 2.3 | -0.4 | 87.9 y/y -3.3% | 7.4 y/y 25.4% | 84.0% | 48.2 | Link |
| 2025-03-31 | Q1 2025 (3M) | OK | 8.1 y/y 9.4% | 1.2 y/y 18.9% | 1.4 y/y -0.9% | 2.6 y/y 7.3% | 1.7 y/y 1631.0% | 1.4 | -0.4 | 89.4 y/y -3.9% | 6.2 y/y 23.6% | 114.5% | 48.6 | Link |
| 2024-12-31 | FY 2024 (12M) | OK | 9.1 y/y 10.9% | 2.3 y/y 81.8% | 1.4 y/y 1.2% | 3.7 y/y 39.9% | 0.6 y/y -18.3% | 4.8 | -0.4 | 91.8 y/y -5.5% | 5.9 y/y -5.7% | 61.0% | 48.2 | Link |
| 2024-09-30 | Q3 2024 (3M) | OK | 8.5 y/y 23.2% | 2.0 y/y 1.3% | 1.4 y/y 56.0% | 3.4 y/y 18.1% | 2.8 y/y 63.6% | 3.6 | -0.3 | 90.9 y/y 0.4% | 7.5 y/y -1.7% | 56.1% | 51.4 | Link |
| 2024-06-30 | Q2 2024 (3M) | OK | 8.4 y/y 20.1% | 1.9 y/y -28.9% | 1.4 y/y 56.2% | 3.3 y/y -7.6% | 0.7 y/y -45.9% | 2.5 | -0.2 | 90.9 y/y 0.7% | 5.9 y/y -12.6% | 54.5% | 53.3 | Link |
| 2024-03-31 | Q1 2024 (3M) | OK | 7.4 y/y 22.0% | 1.0 y/y -48.4% | 1.4 y/y 55.4% | 2.4 y/y -15.3% | -0.1 y/y -104.0% | 0.7 | -0.2 | 93.0 y/y 4.8% | 5.0 y/y -6.1% | -8.0% | 54.3 | Link |
| 2023-12-31 | FY 2023 (12M) | OK | 8.2 y/y — | 1.3 y/y — | 1.4 y/y — | 2.7 y/y — | 0.8 y/y — | 0.5 | -27.2 | 97.2 y/y — | 6.2 y/y — | 96.7% | 53.8 | Link |
| 2023-09-30 | Q3 2023 (3M) | OK | 6.9 y/y — | 2.0 y/y — | 0.9 y/y — | 2.9 y/y — | 1.7 y/y — | 2.8 | -0.2 | 90.5 y/y — | 7.7 y/y — | 32.0% | 25.7 | Link |
| 2023-06-30 | Q2 2023 (3M) | OK | 7.0 y/y — | 2.7 y/y — | 0.9 y/y — | 3.6 y/y — | 1.4 y/y — | 4.1 | -0.3 | 90.3 y/y — | 6.8 y/y — | 91.0% | 27.3 | Link |
| 2023-03-31 | Q1 2023 (3M) | OK | 6.1 y/y — | 1.9 y/y — | 0.9 y/y — | 2.8 y/y — | 2.8 y/y — | 1.1 | -0.3 | 88.7 y/y — | 5.3 y/y — | — | 30.0 | Link |
Quarterly values ($ mln)
Year-over-year change
Net debt / cash ($ mln)
Current 15.0x · 3-year average 16.0x
No dividend rows found for this issuer (checked: Yahoo Finance (ex-div)).
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)